-
Je něco špatně v tomto záznamu ?
Dizocilpine derivatives as neuroprotective NMDA receptor antagonists without psychomimetic side effects
J. Konecny, A. Misiachna, M. Chvojkova, L. Kleteckova, M. Kolcheva, M. Novak, L. Prchal, M. Ladislav, K. Hemelikova, J. Netolicky, M. Hrabinova, T. Kobrlova, JZ. Karasova, J. Pejchal, J. Fibigar, Z. Vecera, T. Kucera, P. Jendelova, P. Zahumenska,...
European journal of medicinal chemistry.
2024 ;
280 (-) :
116981.
[pub] 20241018
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
Perzistentní odkaz
https://www.medvik.cz/link/bmc25003033
- MeSH
- dizocilpinmaleát * farmakologie MeSH
- hematoencefalická bariéra metabolismus účinky léků MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- molekulární struktura MeSH
- neuroprotektivní látky * farmakologie chemie chemická syntéza MeSH
- potkani Sprague-Dawley MeSH
- receptory N-methyl-D-aspartátu * antagonisté a inhibitory metabolismus MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
We aimed to prepare novel dibenzo [a,d][7]annulen derivatives that act on N-methyl-d-aspartate (NMDA) receptors with potential neuroprotective effects. Our approach involved modifying the tropane moiety of MK-801, a potent open-channel blocker known for its psychomimetic side effects, by introducing a seven-membered ring with substituted base moieties specifically to alleviate these undesirable effects. Our in silico analyses showed that these derivatives should have high gastrointestinal absorption and cross the blood-brain barrier (BBB). Our pharmacokinetic studies in rats supported this conclusion and confirmed the ability of leading compounds 3l and 6f to penetrate the BBB. Electrophysiological experiments showed that all compounds exhibited different inhibitory activity towards the two major NMDA receptor subtypes, GluN1/GluN2A and GluN1/GluN2B. Of the selected compounds intentionally differing in the inhibitory efficacy, 6f showed high relative inhibition (∼90 % for GluN1/GluN2A), while 3l showed moderate inhibition (∼50 %). An in vivo toxicity study determined that compounds 3l and 6f were safe at 10 mg/kg doses with no adverse effects. Behavioral studies demonstrated that these compounds did not induce hyperlocomotion or impair prepulse inhibition of startle response in rats. Neuroprotective assays using a model of NMDA-induced hippocampal neurodegeneration showed that compound 3l at a concentration of 30 μM significantly reduced hippocampal damage in rats. These results suggest that these novel dibenzo [a,d][7]annulen derivatives are promising candidates for developing NMDA receptor-targeted therapies with minimal psychotomimetic side effects.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003033
- 003
- CZ-PrNML
- 005
- 20250206104020.0
- 007
- ta
- 008
- 250121e20241018fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2024.116981 $2 doi
- 035 __
- $a (PubMed)39442339
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Konecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 245 10
- $a Dizocilpine derivatives as neuroprotective NMDA receptor antagonists without psychomimetic side effects / $c J. Konecny, A. Misiachna, M. Chvojkova, L. Kleteckova, M. Kolcheva, M. Novak, L. Prchal, M. Ladislav, K. Hemelikova, J. Netolicky, M. Hrabinova, T. Kobrlova, JZ. Karasova, J. Pejchal, J. Fibigar, Z. Vecera, T. Kucera, P. Jendelova, P. Zahumenska, E. Langore, J. Doderovic, YP. Pang, K. Vales, J. Korabecny, O. Soukup, M. Horak
- 520 9_
- $a We aimed to prepare novel dibenzo [a,d][7]annulen derivatives that act on N-methyl-d-aspartate (NMDA) receptors with potential neuroprotective effects. Our approach involved modifying the tropane moiety of MK-801, a potent open-channel blocker known for its psychomimetic side effects, by introducing a seven-membered ring with substituted base moieties specifically to alleviate these undesirable effects. Our in silico analyses showed that these derivatives should have high gastrointestinal absorption and cross the blood-brain barrier (BBB). Our pharmacokinetic studies in rats supported this conclusion and confirmed the ability of leading compounds 3l and 6f to penetrate the BBB. Electrophysiological experiments showed that all compounds exhibited different inhibitory activity towards the two major NMDA receptor subtypes, GluN1/GluN2A and GluN1/GluN2B. Of the selected compounds intentionally differing in the inhibitory efficacy, 6f showed high relative inhibition (∼90 % for GluN1/GluN2A), while 3l showed moderate inhibition (∼50 %). An in vivo toxicity study determined that compounds 3l and 6f were safe at 10 mg/kg doses with no adverse effects. Behavioral studies demonstrated that these compounds did not induce hyperlocomotion or impair prepulse inhibition of startle response in rats. Neuroprotective assays using a model of NMDA-induced hippocampal neurodegeneration showed that compound 3l at a concentration of 30 μM significantly reduced hippocampal damage in rats. These results suggest that these novel dibenzo [a,d][7]annulen derivatives are promising candidates for developing NMDA receptor-targeted therapies with minimal psychotomimetic side effects.
- 650 12
- $a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $x metabolismus $7 D016194
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a neuroprotektivní látky $x farmakologie $x chemie $x chemická syntéza $7 D018696
- 650 12
- $a dizocilpinmaleát $x farmakologie $7 D016291
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a hematoencefalická bariéra $x metabolismus $x účinky léků $7 D001812
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Misiachna, Anna $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Chvojkova, Marketa $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
- 700 1_
- $a Kleteckova, Lenka $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic; National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
- 700 1_
- $a Kolcheva, Marharyta $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Novak, Martin $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Prchal, Lukas $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Ladislav, Marek $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Hemelikova, Katarina $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Netolicky, Jakub $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Hrabinova, Martina $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 700 1_
- $a Kobrlova, Tereza $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Karasova, Jana Zdarova $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 700 1_
- $a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 700 1_
- $a Fibigar, Jakub $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 700 1_
- $a Vecera, Zbynek $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 700 1_
- $a Kucera, Tomas $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 700 1_
- $a Jendelova, Pavla $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Zahumenska, Petra $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Langore, Emily $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Doderovic, Jovana $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
- 700 1_
- $a Pang, Yuan-Ping $u Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN, USA
- 700 1_
- $a Vales, Karel $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic; National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
- 700 1_
- $a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 700 1_
- $a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic. Electronic address: ondrej.soukup@fnhk.cz
- 700 1_
- $a Horak, Martin $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic. Electronic address: martin.horak@iem.cas.cz
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 280 (20241018), s. 116981
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39442339 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104015 $b ABA008
- 999 __
- $a ok $b bmc $g 2263050 $s 1239040
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 280 $c - $d 116981 $e 20241018 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20250121
